Anti-SLC6A16 monoclonal antibody

Pre-made anti-SLC6A16 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SLC6A16/SLC6A16 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1745-Ab-1/ GM-Tg-hg-IP1745-Ab-2Anti-Human SLC6A16 monoclonal antibodyHuman
GM-Tg-rg-IP1745-Ab-1/ GM-Tg-rg-IP1745-Ab-2Anti-Rat SLC6A16 monoclonal antibodyRat
GM-Tg-mg-IP1745-Ab-1/ GM-Tg-mg-IP1745-Ab-2Anti-Mouse SLC6A16 monoclonal antibodyMouse
GM-Tg-cynog-IP1745-Ab-1/ GM-Tg-cynog-IP1745-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC6A16 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1745-Ab-1/ GM-Tg-felg-IP1745-Ab-2Anti-Feline SLC6A16 monoclonal antibodyFeline
GM-Tg-cang-IP1745-Ab-1/ GM-Tg-cang-IP1745-Ab-2Anti-Canine SLC6A16 monoclonal antibodyCanine
GM-Tg-bovg-IP1745-Ab-1/ GM-Tg-bovg-IP1745-Ab-2Anti-Bovine SLC6A16 monoclonal antibodyBovine
GM-Tg-equg-IP1745-Ab-1/ GM-Tg-equg-IP1745-Ab-2Anti-Equine SLC6A16 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1745-Ab-1/ GM-Tg-hg-IP1745-Ab-2; GM-Tg-rg-IP1745-Ab-1/ GM-Tg-rg-IP1745-Ab-2;
GM-Tg-mg-IP1745-Ab-1/ GM-Tg-mg-IP1745-Ab-2; GM-Tg-cynog-IP1745-Ab-1/ GM-Tg-cynog-IP1745-Ab-2;
GM-Tg-felg-IP1745-Ab-1/ GM-Tg-felg-IP1745-Ab-2; GM-Tg-cang-IP1745-Ab-1/ GM-Tg-cang-IP1745-Ab-2;
GM-Tg-bovg-IP1745-Ab-1/ GM-Tg-bovg-IP1745-Ab-2; GM-Tg-equg-IP1745-Ab-1/ GM-Tg-equg-IP1745-Ab-2
Products NameAnti-SLC6A16 monoclonal antibody
Formatmab
Target NameSLC6A16
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SLC6A16 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1745-Ag-1Recombinant multi-species S6A16/ SLC6A16/ NT5 protein


    Target information

    Target IDGM-IP1745
    Target NameSLC6A16
    Gene ID28968,381884,292902,718690,484383,101082794,785362
    Gene Symbol and SynonymsGm1084,NT5,NTT5,RGD1561338,SLC6A16
    Uniprot AccessionQ9GZN6
    Uniprot Entry NameS6A16_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000063127
    Target ClassificationN/A

    The target: SLC6A16, gene name: SLC6A16, also named as NT5, NTT5. SLC6A16 shows structural characteristics of an Na(+)- and Cl(-)-dependent neurotransmitter transporter, including 12 transmembrane (™) domains, intracellular N and C termini, and large extracellular loops containing multiple N-glycosylation sites.[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.